Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer.
Nano Lett. 2005 Dec; 5(12):2426-31.NL

Abstract

Photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD) was evaluated using a supramolecular nanomedical device, that is, a novel dendritic photosensitizer (DP) encapsulated by a polymeric micelle formulation. The characteristic dendritic structure of the DP prevents aggregation of its core sensitizer, thereby inducing a highly effective photochemical reaction. With its highly selective accumulation on choroidal neovascularization (CNV) lesions, this treatment resulted in a remarkably efficacious CNV occlusion with minimal unfavorable phototoxicity.

Links

Publisher Full Text

Authors+Show Affiliations

Ideta R
Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Tasaka F
No affiliation info available
Jang WD
No affiliation info available
Nishiyama N
No affiliation info available
Zhang GD
No affiliation info available
Harada A
No affiliation info available
Yanagi Y
No affiliation info available
Tamaki Y
No affiliation info available
Aida T
No affiliation info available
Kataoka K
No affiliation info available

MeSH

AnimalsDrug CarriersGlaucoma, NeovascularMacromolecular SubstancesMaleNanotechnologyPhotochemotherapyPhotosensitizing AgentsPorphyrinsRats

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16351191